XML 174 R22.htm IDEA: XBRL DOCUMENT v3.20.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)

3 Months Ended

Mar. 31, 2020

Kite Pharma Inc

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement for the three months ended March 31, 2020 and 2019 were as follows (in thousands):

			Three Months Ended March 31,
			2020						2019
Revenue related to Kite agreement:
Recognition of license and stand-ready fee			$	6,227					$	6,159
Research services			992						2,153
Total			$	7,219					$	8,312

Pfizer SB-525

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement for the three months ended March 31, 2020 and 2019 were as follows (in thousands):

			Three Months Ended March 31,
			2020						2019
Revenue related to Pfizer SB-525 agreement:
Recognition of upfront fee and research services			$	2,190					$	(3,040)
Milestone achievement			993						—
Total			$	3,183					$	(3,040)

Pfizer

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement for the three months ended March 31, 2020 and 2019 were as follows (in thousands):

			Three Months Ended March 31,
			2020						2019
Recognition of upfront fee related to Pfizer C9ORF72 agreement			$	360					$	615

Sanofi

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement for the three months ended March 31, 2020 and 2019 were as follows (in thousands):

			Three Months Ended March 31,
			2020						2019
Revenue related to Sanofi agreement:
Recognition of upfront fee			$	(729)					$	752
Research services			1,720						1,197
Milestone achievement			(492)						—
Total			$	499					$	1,949

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: